Positive, phase 3 data for once-daily JNJ-2113 (icotrokinra) has been announced by Protagonist Therapeutics in collaboration with Johnson & Johnson that demonstrated "significant" skin clearance ...

Reviewing the AAP's sudden infant death syndrome 2022 guidelines ...

Reviewing the AAP's sudden infant death syndrome 2022 guidelines ...

A further understanding of the role SARS-CoV-2 plays in T2D incidence can add an important component to benefit and risk considerations to prevent COVID-19. In a retrospective cohort study of nearly ...

Reviewing the AAP's sudden infant death syndrome 2022 guidelines ...

Stephanie Anne Deutsch, MD, MS, MSCR, FAAP, joined us to discuss a new study that highlighted SUID among infants who were prenatally substance exposed. It it known that maternal substance use during ...

Reviewing the AAP's sudden infant death syndrome 2022 guidelines ...

Reviewing the AAP's sudden infant death syndrome 2022 guidelines ...

Rakesh Jain, MD, MPH discusses once-daily clonidine hydrochloride (ONYDA XR) for ADHD ...

Rakesh Jain, MD, MPH discusses once-daily clonidine hydrochloride (ONYDA XR) for ADHD ...

Rakesh Jain, MD, MPH discusses once-daily clonidine hydrochloride (ONYDA XR) for ADHD ...

Rakesh Jain, MD, MPH discusses once-daily clonidine hydrochloride (ONYDA XR) for ADHD ...